HRP20192256T1 - Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta - Google Patents
Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta Download PDFInfo
- Publication number
- HRP20192256T1 HRP20192256T1 HRP20192256TT HRP20192256T HRP20192256T1 HR P20192256 T1 HRP20192256 T1 HR P20192256T1 HR P20192256T T HRP20192256T T HR P20192256TT HR P20192256 T HRP20192256 T HR P20192256T HR P20192256 T1 HRP20192256 T1 HR P20192256T1
- Authority
- HR
- Croatia
- Prior art keywords
- cabergoline
- treatment
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title claims 5
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title claims 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims 3
- 229960004596 cabergoline Drugs 0.000 title claims 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (3)
1. Kabergolin za uporabu u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta, naznačen time što je očna bolest izabrana između dijabetičkog makularnog edema, dijabetičke retinopatije, dobno povezane makularne degeneracije, okluzije retinalne arterije, okluzije retinalne vene i koroidne neovaskularizacije.
2. Farmaceutski pripravak koji sadrži kabergolin kao aktivni sastojak za uporabu u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta, naznačen time što je očna bolest izabrana između dijabetičkog makularnog edema, dijabetičke retinopatije, dobno povezane makularne degeneracije, okluzije retinalne arterije, okluzije retinalne vene i koroidne neovaskularizacije.
3. Pripravak za uporabu prema zahtjevu 2 za oralnu primjenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415170A PL232974B1 (pl) | 2015-12-09 | 2015-12-09 | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
| PCT/IB2016/057483 WO2017098461A1 (en) | 2015-12-09 | 2016-12-09 | Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels |
| EP16831636.2A EP3386509B1 (en) | 2015-12-09 | 2016-12-09 | Use of cabergoline in the treatment of eye diseases caused by elevated vascular endothelial growth factor levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192256T1 true HRP20192256T1 (hr) | 2020-03-06 |
Family
ID=57909808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192256TT HRP20192256T1 (hr) | 2015-12-09 | 2019-12-16 | Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180360820A1 (hr) |
| EP (1) | EP3386509B1 (hr) |
| CN (1) | CN108472294B (hr) |
| CA (1) | CA3007953C (hr) |
| DK (1) | DK3386509T3 (hr) |
| ES (1) | ES2761875T3 (hr) |
| HR (1) | HRP20192256T1 (hr) |
| IL (1) | IL259903B (hr) |
| LT (1) | LT3386509T (hr) |
| PL (2) | PL232974B1 (hr) |
| PT (1) | PT3386509T (hr) |
| RU (1) | RU2698728C1 (hr) |
| WO (1) | WO2017098461A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL241086B1 (pl) * | 2017-09-26 | 2022-08-01 | Oseka Maciej | Pergolid do zastosowania w leczeniu zakrzepu naczyń siatkówki i/lub zatoru naczyń siatkówki oraz kompozycja farmaceutyczna zawierająca pergolid |
| PL430675A1 (pl) * | 2019-07-23 | 2021-01-25 | Osęka Maciej | Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| US6114326A (en) * | 1998-03-27 | 2000-09-05 | Pharmacia & Upjohn Company | Use of cabergoline in the treatment of restless legs syndrome |
| EA200300125A1 (ru) * | 1998-05-15 | 2003-06-26 | Фармация Энд Апджон Компани | Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича |
| US20070155770A1 (en) * | 2006-01-03 | 2007-07-05 | Cedars-Sinai Medical Center | Treatment of anoragasmia or delayed orgasm |
| KR100923195B1 (ko) * | 2006-04-04 | 2009-10-22 | 고려대학교 산학협력단 | 도파민 ｄ2 수용체에 의한 도파민성 수용체 발달의 조절방법 및 이의 조성물 |
| JP2008308489A (ja) * | 2007-05-11 | 2008-12-25 | Santen Pharmaceut Co Ltd | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 |
| CN102791134B (zh) * | 2009-12-04 | 2015-04-22 | 魄金莱默有限公司 | 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法 |
-
2015
- 2015-12-09 PL PL415170A patent/PL232974B1/pl unknown
-
2016
- 2016-12-09 ES ES16831636T patent/ES2761875T3/es active Active
- 2016-12-09 PT PT168316362T patent/PT3386509T/pt unknown
- 2016-12-09 PL PL16831636T patent/PL3386509T3/pl unknown
- 2016-12-09 US US16/060,517 patent/US20180360820A1/en not_active Abandoned
- 2016-12-09 EP EP16831636.2A patent/EP3386509B1/en active Active
- 2016-12-09 CN CN201680072556.9A patent/CN108472294B/zh active Active
- 2016-12-09 CA CA3007953A patent/CA3007953C/en active Active
- 2016-12-09 WO PCT/IB2016/057483 patent/WO2017098461A1/en active Application Filing
- 2016-12-09 RU RU2018124858A patent/RU2698728C1/ru active
- 2016-12-09 DK DK16831636.2T patent/DK3386509T3/da active
- 2016-12-09 LT LTEP16831636.2T patent/LT3386509T/lt unknown
-
2018
- 2018-06-07 IL IL259903A patent/IL259903B/en active IP Right Grant
-
2019
- 2019-12-16 HR HRP20192256TT patent/HRP20192256T1/hr unknown
-
2020
- 2020-03-31 US US16/836,168 patent/US11324740B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2698728C1 (ru) | 2019-08-29 |
| DK3386509T3 (da) | 2019-12-16 |
| WO2017098461A1 (en) | 2017-06-15 |
| CA3007953C (en) | 2022-11-29 |
| CN108472294B (zh) | 2021-07-13 |
| PT3386509T (pt) | 2019-12-30 |
| US20180360820A1 (en) | 2018-12-20 |
| ES2761875T3 (es) | 2020-05-21 |
| EP3386509A1 (en) | 2018-10-17 |
| US11324740B2 (en) | 2022-05-10 |
| PL3386509T3 (pl) | 2020-08-24 |
| US20200222387A1 (en) | 2020-07-16 |
| EP3386509B1 (en) | 2019-09-18 |
| PL415170A1 (pl) | 2017-06-19 |
| IL259903B (en) | 2020-09-30 |
| IL259903A (en) | 2018-07-31 |
| CA3007953A1 (en) | 2017-06-15 |
| CN108472294A (zh) | 2018-08-31 |
| LT3386509T (lt) | 2020-01-27 |
| PL232974B1 (pl) | 2019-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192256T1 (hr) | Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta | |
| MX2021006092A (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. | |
| PH12017501097A1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| WO2015095772A3 (en) | Formulations and methods for targeted ocular delivery of therapeutic agents | |
| MX361520B (es) | Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas. | |
| MX2019008963A (es) | Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico. | |
| MX2019001021A (es) | Formulaciones de liposomas. | |
| HRP20191131T1 (hr) | Pripravak za zdravlje očiju | |
| JP2013528563A5 (hr) | ||
| MY176525A (en) | Therapeutic agent for ocular disease or prophylactic agent for ocular disease | |
| EP3405159A4 (en) | TREATMENT AND PREVENTION OF RETINAL VASCULAR DISEASE BY PHOTOCOAGULATION | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. | |
| SG11201408323RA (en) | Prophylactic and/or therapeutic agent for mild cognitive impairment | |
| PH12020551015A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| EP4245295A3 (en) | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| Winter et al. | Anti-VEGF treating macular oedema caused by retinal arteriovenous malformation-a case report. | |
| RU2016142578A (ru) | Производное алкинилиндазола и его применение | |
| RU2017102407A (ru) | Применение экстракта cistanche tubulosa в получении лекарственных средств или продуктов питания для защиты клеток глаза | |
| EP3787609A4 (en) | EYE DROP FORMULATION AND PROLONGED METHOD OF DRUG ADMINISTRATION TO THE RETINAL | |
| Ewe et al. | Masquerade macular exudation in Mallatia Leventinese | |
| RU2015154876A (ru) | Способ хирургического лечения диабетического макулярного отека с наличием витреомакулярной тракции | |
| Dzuba et al. | PREVENTION OF THE POSTOPERATIVE MACULAR EDEMA IN PATIENTS AFTER PHACOEMULSIFICATION OF CATARACT | |
| PH12017501796A1 (en) | Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient |